

- (1) Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. medRxiv. 2020;Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1>
- (2) Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. N Engl J Med. 2020; Published online ahead of print. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32706953>.
- (3) Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32896292>.
- (4) Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020; Published online ahead of print. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32379955>.
- (5) Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323(24):2493-2502. Available at: <https://pubmed.ncbi.nlm.nih.gov/32392282/>
- (6) Chaccour C, Hammann F, Ramon-Garcia S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32314704>.
- (7) Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122-1133. Available at: <https://pubmed.ncbi.nlm.nih.gov/12362927/>
- (8) Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2020;103:214-216. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33278625>.
- (9) Chachar AZK, Khan KA, Asif M, Tanveer K, Khaqan A, Basri R. Effectiveness of ivermectin in SARS-COV-2/COVID-19 Patients. Int J of Sci. 2020;9:31-35. Available at: <https://www.ijsciences.com/pub/article/2378>.
- (10) Chowdhury ATMM, Shahbaz M, Karim MR, Islam J, Guo D, He S. A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients. Research Square. 2020;Preprint. Available

at: <https://assets.researchsquare.com/files/rs-38896/v1/3ee350c3-9d3f-4253-85f9-1f17f3af9551.pdf>.

- (11) Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, Araujo-Castillo RV. Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. medRxiv. 2020. Available at: <https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v3.full>
- (12) Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33031764>.
- (13) WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity Trial results. N Engl J Med. 2020. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa2023184>
- (14) Lamarche J, Nair R, Peguero A and Courville C. Vitamin C-Induced Oxalate Nephropathy. Int J Nephrol 2011; 2011: 146927 Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096888/>
- (15) Marcinowska-Suchowierska E et al. Vitamin D Toxicity- A Clinical Perspective. Front Endocrinol (Lausanne) 2018;9:550. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158375/>
- (16) Alansari K et al. Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics 2019;143:e20182308. doi:10.1542/peds.2018-2308 pmid:30760509. Available at: <https://pubmed.ncbi.nlm.nih.gov/30760509/>
- (17) Beigel H.. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis 2018;31:527-34. doi:10.1097/QCO.0000000000000499 pmid:30299360. Available at: <https://pubmed.ncbi.nlm.nih.gov/30299360/>
- (18) Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Convalescent plasma for COVID-19: a randomized clinical trial. medRxiv. 2020;Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2020.07.01.20139857v1>.
- (19) Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv. 2020;Preprint. Available at: <https://www.medrxiv.org/content/10.1101/2020.09.03.20187252v2>.

- (20) Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. *JAMA*. 2020. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32492084>.
- (21) Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. *Mayo Clinical Proceedings*. 2020. Available at: [https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/jmcp/jmcp\\_ft9\\_5\\_6\\_8.pdf](https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/jmcp/jmcp_ft9_5_6_8.pdf). Accessed June 26, 2020.
- (22) Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. *medRxiv*. 2020. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32817978>.
- (23) Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. 2021. Available at: <https://www.fda.gov/media/145802/download>. Accessed February 22, 2021.
- (24) Food and Drug Administration. Frequently asked questions on the Emergency Use Authorization for bamlanivimab and etesevimab. 2021. Available at: <https://www.fda.gov/media/145808/download>.
- (25) Horby P, Lim WS et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. *N Engl J Med*. 2020; (published online July 17.) Available at: <https://doi.org/10.1056/NEJMoa2021436>
- (26) Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. *JAMA*. 2020; 324: 1298-1306
- (27) Tomazini BM et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. *JAMA*. 2020; 324: 1307-1316
- (28) Angus DC et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. *JAMA*. 2020; 324: 1317-1329
- (29) Rosas I et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. *medRxiv*. 2020. Available at: <https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2>.
- (30) Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. *N Engl J Med*. 2020. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33332779>.
- (31) The REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19—preliminary report. *medRxiv*. 2021. Available at: <https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v1>.